For decades, Aspirin in low doses It was the silent ally of millions of patients at cardiovascular risk. However, new scientific evidence could change that centennial medical routine: the clopidogrelan anticoagulant already present in clinical practice, proved to be more effective and sure that the classic white pill.
The finding, presented at the Congress of the European Society of Cardiology in Madrid and published in the prestigious magazine The Lancetbrings together data from an international study that analyzed almost 29,000 people with coronary arterial disease. The researchers concluded that clopidogrel not only reduces more effectively the possibility of suffering infarctions and strokes, but also does not increase the risk of bleeding, one of the usual concerns with anticoagulants.
Coronary arterial disease – the most common of heart ailments and one of the main causes of death in the world – affects more than 300 million people. It occurs when the arteries that feed to the heart narrow themselves by the accumulation of fat on their walls, which generates angina perteced and, in severe cases, infarctions. For decades, the indication of a daily aspirin was the preventive response par excellence.
But the new results reconfigure that paradigm. The clopidogrel, which until now was prescribed in specific situations, appears as a candidate to become the reference treatment. The team of specialists from United States, United Kingdom, Australia, Switzerland and Japan It was sharp, the evidence supports an “extensive adoption” of the drug in clinical practice.
If its large -scale implementation is confirmed, change would imply a transformation in global medical guidelines, displacing the aspirin of his historical place. It is not just a therapeutic nuance: the turn could redefine the way in which it seeks to prevent the first cause of death of the planet.
Image gallery
